RT Journal
A1 Rapado AA, Castrillo JM, Díaz-Curiel MM
T1 USe of diet and probucol
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 1979
FD September 1
VO 139
IS 9
SP 1062
OP 1063
DO 10.1001/archinte.1979.03630460092033
UL http://dx.doi.org/10.1001/archinte.1979.03630460092033
AB To the Editor.— 
    Reference has been made in the Archives (137:1429-1434, 1977) to the use of diet and probucol for lowering plasma cholesterol in type II hyperlipoproteinemia, thus confirming other reports in the literature.1 We have used this drug in a 12-year-old girl with homozygous hypercholesterolemia who had diffuse xanthomas and a positive treadmill ECG. Three months after treatment with diet plus 16 g/day of cholestyramine resin, bone pain, growth retardation, and a sharp rise in alkaline phosphatase levels developed in the patient, with radiologic signs of rickets. These abnormalities withdrew with high doses of intramuscularly given cholecalciferol (Figure). After including probucol in her treatment, dosages of cholestyramine and cholecalciferol could be suppressed without observing any changes in cholesterol or alkaline phosphatase concentrations. She is now symptom-free with no growing of xanthomas and a normal treadmill ECG.As work in progress in our institution has demonstrated, by means of